APA (7th ed.) Citation

Mai, E. K., Raab, M., Neben, K., Goldschmidt, H., Bertsch, U., Jauch, A., . . . Hillengaß, J. (2015). Phase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myeloma. Leukemia, 29(8), . https://doi.org/10.1038/leu.2015.80

Chicago Style (17th ed.) Citation

Mai, Elias K., et al. "Phase III Trial of Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Versus Bortezomib, Doxorubicin, Dexamethasone (PAd) in Newly-diagnosed Myeloma." Leukemia 29, no. 8 (2015). https://doi.org/10.1038/leu.2015.80.

MLA (9th ed.) Citation

Mai, Elias K., et al. "Phase III Trial of Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Versus Bortezomib, Doxorubicin, Dexamethasone (PAd) in Newly-diagnosed Myeloma." Leukemia, vol. 29, no. 8, 2015, https://doi.org/10.1038/leu.2015.80.